Denali Therapeutics Inc. (Nasdaq: DNLI) has entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE